Patents by Inventor Kaixian Chen

Kaixian Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150284331
    Abstract: The present invention relates to the field of pharmaceutical chemistry and pharmacotherapeutics, and in particular to compounds of general formula I, racemates, R-isomers, S-isomers, and pharmaceutically acceptable salts thereof and their mixtures, and the preparation methods thereof and a pharmaceutical composition containing the compounds and uses thereof as an acetylcholine esterase inhibitor.
    Type: Application
    Filed: October 17, 2013
    Publication date: October 8, 2015
    Inventors: Hong Liu, Haiyan Zhang, Yu Zhou, Yan Fu, Hualiang Jiang, Xican Tang, Kaixian Chen
  • Publication number: 20150231090
    Abstract: The present invention provides composition for treating cancer comprising polyprenylated acylphloroglucinol (PPAP) compound. The present invention also provides a composition comprising Guttiferone K for treating esophageal cancer and liver cancer. The present invention further provides a method of using said compound for inhibiting cancer metastasis.
    Type: Application
    Filed: May 1, 2015
    Publication date: August 20, 2015
    Inventors: Hongxi XU, Kaikai SHEN, Yuanzhi LAO, Hongsheng TAN, Kaixian CHEN, Dajian YANG, Shilin CHEN, Zhaoxiang BIAN, Chengyuan LIN, Aiping LU, Albert Sun Chi CHAN
  • Publication number: 20150210711
    Abstract: The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (I) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor. The bioactivity experiment demonstrates that, the compound is expected to be developed into a novel and potent chemical entity for treating diseases associated with dopamine receptor and 5-hydroxytryptamine receptor, especially schizophrenia, Parkinson's disease, drug addiction, migraine and so on.
    Type: Application
    Filed: April 10, 2015
    Publication date: July 30, 2015
    Inventors: Hong LIU, Xin XIE, Xuechu ZHEN, Haifeng SUN, Jing LI, Liyuan ZHU, Zeng LI, Ying CHEN, Hualiang JIANG, Kaixian CHEN
  • Publication number: 20150196612
    Abstract: The present invention discloses a novel composition with anti-viral effects comprises extracts from Anemarrhena asphodeloides. Method of preparing said extract is also disclosed.
    Type: Application
    Filed: January 10, 2014
    Publication date: July 16, 2015
    Applicants: Shanghai University of Traditional Chinese Medicine, Hong Kong Baptist University
    Inventors: Quanbin HAN, Aiping LU, Zhaoxiang BIAN, Hongxi XU, Mengshun LIU, Ling TAO, Mengjie WANG, Kaixian CHEN
  • Patent number: 9045491
    Abstract: Disclosed are new thienyl [3,2-d] pyrimidin-4-one compounds shown as the general formula (I), preparation method, pharmaceutical compositions and pharmacological use thereof. The compounds are strong DPPIV (dipeptide peptidase IV) inhibitors and can treat type II diabetes through well inhibiting DPPIV indirectly increasing the content of GLP-1 in vivo and inducing a series of physiological actions in vivo. Therefore, the compounds could be developed as new promising drugs for treating diabetes.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: June 2, 2015
    Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Cisen Pharmaceutical Co., Ltd.
    Inventors: Hong Liu, Jia Li, Jian Li, Jingya Li, Jiang Wang, Mingbo Su, Jie Lian, Hualiang Jiang, Kaixian Chen
  • Publication number: 20150141419
    Abstract: The present invention relates to a diarylo[a,g]quinolizidine compound of formula (I), enantiomer, diastereoisomer, racemate, mixture, pharmaceutically acceptable salt, crystalline hydrate or solvate thereof; the preparation method thereof, and uses thereof in preparing an experimental model drugs related to dopamine receptors and 5-HT receptors or a medicament for treating or preventing a disease related to dopamine receptors and 5-HT receptors.
    Type: Application
    Filed: May 9, 2013
    Publication date: May 21, 2015
    Inventors: Hong Liu, Xuechu Zhen, Haifeng Sun, Liyuan Zhu, Wangke Qian, Leiping Yu, Zeng Li, Shengbin Zhou, Wenxian Cai, Hualiang Jiang, Kaixian Chen
  • Publication number: 20150038569
    Abstract: Cervical cancer is one of the most common malignancies and is associated with a dismal prognosis. The most common therapeutic option for cervical cancer consists of surgery in early stages, and chemotherapy or radiotherapy in more advanced stages of the disease. Although treatment options have increased for some patients, overall progress has been modest. This invention relates to a method for treating cancer comprising administering an anti-cancer compound. More particularly, the present invention relates to an anti-cervical-cancer compound for treating human cervical cancer and tumor.
    Type: Application
    Filed: July 31, 2014
    Publication date: February 5, 2015
    Inventors: Hongxi XU, Hong ZHANG, Yuanzhi LAO, Xiaoyu WANG, Kaixian CHEN, Dajian YANG, Shilin CHEN, Chengyuan LIN, Zhaoxiang BIAN, Aiping LU, Albert Sun Chi CHAN
  • Publication number: 20150025155
    Abstract: Prostate cancer is the most commonly diagnosed cancer in males and one of the leading causes of cancer death. Although treatment options have increased for some patients, overall progress has been modest. Thus, there is a great need to develop new treatments. This invention relates to a method for treating cancer comprising using an anti-cancer compound. More particularly, it relates to an anti-prostate cancer compound that can be isolated from Garcinia esculenta or chemically synthesized and its specific anticancer/antitumor activity. The invention has a specific application in treating human prostate cancer.
    Type: Application
    Filed: July 17, 2014
    Publication date: January 22, 2015
    Inventors: Hongxi XU, Xin LI, Hong ZHANG, Yuanzhi LAO, Hongsheng TAN, Xiaoyu WANG, Kaixian CHEN, Zhaoxiang BIAN, Dajian YANG, Shilin CHEN, Aiping LU, Albert Sun Chi CHAN
  • Publication number: 20150011646
    Abstract: This invention is related to compounds isolated from various Garcinia species and method of treating cancer. The present invention provides composition for treating cancer comprising polyprenylated acylphloroglucinol (PPAP) compound. The present invention also provides a composition comprising Guttiferone K for treating esophageal cancer.
    Type: Application
    Filed: January 8, 2014
    Publication date: January 8, 2015
    Applicant: Hong Kong Baptist University
    Inventors: Hongxi XU, Yuanzhi LAO, Zhichao XI, Hongsheng TAN, Kaixian CHEN, Zhaoxiang BIAN, Dajian YANG, Shilin CHEN, Aiping LU, Albert Sun Chi CHAN
  • Publication number: 20140323466
    Abstract: Disclosed are new thienyl[3,2-d]pyrimidin-4-one compounds shown as the general formula (I), preparation method, pharmaceutical compositions and pharmacological use thereof. The compounds are strong DPPIV (dipeptide peptidase IV) inhibitors and can treat type II diabetes through well inhibiting DPPIV indirectly increasing the content of GLP-1 in vivo and inducing a series of physiological actions in vivo. Therefore, the compounds could be developed as new promising drugs for treating diabetes.
    Type: Application
    Filed: October 23, 2012
    Publication date: October 30, 2014
    Inventors: Hong Liu, Jia Li, Jian Li, Jingya Li, Jiang Wang, Mingbo Su, Jie Lian, Hualiang Jiang, Kaixian Chen
  • Publication number: 20140235877
    Abstract: The present invention provides two compounds, namely Compound A and B, as the potential anticancer drug, and a composition comprising said Compound A and/or B for treating cancer or tumor related diseases. The present invention also relates to methods of preparing the compounds from a natural source and a composition comprising the compounds, and using the same for treating cancer or tumor related diseases.
    Type: Application
    Filed: March 31, 2014
    Publication date: August 21, 2014
    Applicant: Hong Kong Baptist University
    Inventors: Hongxi XU, Zhengxiang XIA, Yuanzhi LAO, Hongsheng TAN, Zhaoxiang BIAN, Dajian YANG, Shilin CHEN, Kaixian CHEN, Albert Sun-Chi CHAN
  • Publication number: 20140200265
    Abstract: This invention relates to the use of a natural compound from natural sources for its therapeutic uses. More particularly, it relates to a compound 1,3,5,7-tetrahydroxy-8-isoprenylxanthone (TI, FIG. 1), that is naturally occurring in the plant of Garcinia esculenta Y. H. Li, and its biological activity of inhibiting nitric oxide production and microRNA 155 expression in stimulated macrophages, which can be developed as potential anti-inflammatory drugs.
    Type: Application
    Filed: January 8, 2014
    Publication date: July 17, 2014
    Applicant: Hong Kong Baptist University
    Inventors: Hongxi Xu, Dandan Zhang, Hong Zhang, Kaixian Chen, Zhaoxiang Bian, Chengyuan Lin, Dajian Yang, Shilin Chen, Aiping Lu, Albert Sun Chi Chan
  • Publication number: 20140194499
    Abstract: Two novel polyprenylated benzoylphloroglucinol derivatives, garciesculentones A and C, are disclosed in the present invention. Garciesculentones A and C exhibit cytotoxicity and/or antimigration effect against various cancer cell lines. The experimental results of the present invention suggest that Garciesculentones A and C are useful for developing into anticancer drugs.
    Type: Application
    Filed: January 9, 2014
    Publication date: July 10, 2014
    Applicant: Hong Kong Baptist University
    Inventors: Hongxi XU, Hong ZHANG, Yuanzhi LAO, Dandan ZHANG, Kaixian CHEN, Zhaoxiang BIAN, Chengyuan LIN, Dajian YANG, Shilin CHEN, Aiping LU, Albert Sun Chi CHAN
  • Publication number: 20140194529
    Abstract: This invention relates to the use of a compound from natural sources for therapeutic uses. More particularly, it relates to a compound, Garcimultiflorone E, naturally occurring in the plant of Garcinia esculenta Y. H. Li which has potent anti-inflammation and anti-cancer effect.
    Type: Application
    Filed: January 8, 2014
    Publication date: July 10, 2014
    Applicant: Hong Kong Baptist University
    Inventors: Hongxi XU, Dandan ZHANG, Hong ZHANG, Kaixian CHEN, Zhaoxiang BIAN, Chengyuan LIN, Dajian YANG, Shilin CHEN, Aiping LU, Albert Sun Chi CHAN
  • Publication number: 20140194528
    Abstract: The present invention relates to a synthetic compound and its therapeutic uses.
    Type: Application
    Filed: January 8, 2014
    Publication date: July 10, 2014
    Applicant: Hong Kong Baptist University
    Inventors: Hongxi XU, Yunhui SHEN, Yuanzhi LAO, Kaixian CHEN, Dajian YANG, Shilin CHEN, Zhaoxiang BIAN, Aiping LU, Albert Sun Chi CHAN, Chengyuan LIN
  • Publication number: 20140194498
    Abstract: A novel polyisoprenylated tetracyclic xanthone, named garciesculentone B, isolated from Garcinia esculenta Y. H. Li is disclosed in the present invention. This compound is shown to have significant cytotoxicity against various cancer cells. In addition, garciesculentone B is shown to have antimigration effect on various cancer cells such as human esophageal carcinoma cell. The experimental data supports that this compound is useful for developing into an anticancer drug.
    Type: Application
    Filed: January 8, 2014
    Publication date: July 10, 2014
    Applicant: Hong Kong Baptist University
    Inventors: Hongxi XU, Hong ZHANG, Zhichao XI, Hongsheng TAN, Kaixian CHEN, Zhaoxiang BIAN, Dajian YANG, Shilin CHEN, Aiping LU, Albert Sun Chi CHAN
  • Publication number: 20140194530
    Abstract: Disclosed is a natural compound, Oblongifolin C, isolated from a natural plant comprising Garcinia species such as Garcinia yunnanesis Hu, for its effects of anti-migration and anti-invasion against cancer and its use as an anticancer drug. The treated cancers comprise cervical cancers and esophageal cancers. The cancer treatment comprises inhibition of cancer metastasis and inhibition of autophagic flux.
    Type: Application
    Filed: January 9, 2014
    Publication date: July 10, 2014
    Applicant: Hong Kong Baptist University
    Inventors: Hongxi Xu, Yuanzhi Lao, Hongsheng Tan, Naihan Xu, Xiaoyu Wang, Zhenyan Liu, Kaixian Chen, Zhaoxiang Bian, Dajian Yang, Shilin Chen, Aiping Lu, Albert Sun Chi Chan
  • Publication number: 20140088130
    Abstract: The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (I) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor. The bioactivity experiment demonstrates that, the compound is expected to be developed into a novel and potent chemical entity for treating diseases associated with dopamine receptor and 5-hydroxytryptamine receptor, especially schizophrenia, Parkinson's disease, drug addiction, migraine and so on.
    Type: Application
    Filed: November 27, 2013
    Publication date: March 27, 2014
    Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Hong LIU, Xin XIE, Xuechu ZHEN, Haifeng SUN, Jing LI, Liyuan ZHU, Zeng LI, Ying CHEN, Hualiang JIANG, Kaixian CHEN
  • Patent number: 7662860
    Abstract: The present invention discloses 3D-structure of SARS-CoV Viral 3CL Protease obtained through molecular simulation. The 3D-structure is used as a drug target for screening the existing medical database CMC (Comprehensive Medicinal Chemistry, MDL Information System, Inc.), and a group of compounds which have the activity of inhibiting SARS-CoV virus 3CL Protease are found. Cinanserin was tested at molecular and viral levels, and it was found to be able to inhibit the SARS-CoV viral 3CL protease and SARS-CoV viruses. Cinanserin analogs were synthesized and tested at molecular and viral levels, they were found to be able to inhibit the SARS-CoV virus 3CL Protease and SARS-CoV viruses, and may be used for treating and/or preventing SARS-CoV virus infection.
    Type: Grant
    Filed: December 2, 2005
    Date of Patent: February 16, 2010
    Assignees: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai Lead Discovery Pharmaceuticals Limited Company
    Inventors: Jianhua Shen, Hualiang Jiang, Xu Shen, Jianping Zuo, Xiaomin Luo, Donglu Bai, Jingkang Shen, Kaixian Chen, Chunshan Gui, Lili Chen, Jing Chen, Yifu Yang, Xianhan Zhuang, Yiming Yang, Xuchang He, Hong Liu, Bing Xiong, Haibin Luo, Tao Sun, Fei Ye
  • Publication number: 20090182133
    Abstract: The invention relates to pharmaceutical compositions comprising benzopyranone derivatives for the treatment of Severe Acute Respiratory Syndrome (SARS).
    Type: Application
    Filed: December 15, 2006
    Publication date: July 16, 2009
    Inventors: Chum Mok Puah, Weiliang Zhu, Jian Li, Lili Chen, Cheng Luo, Gang Chen, Zhili Zuo, Xiaomin Luo, Xu Shen, Kaixian Chen, Hualiang Jiang